Lupin's Mandideep Unit-2 Facility Completes U.S. FDA Inspection with No Observations

Global pharma major Lupin Limited (Lupin) has announced that its Unit-2 manufacturing facility located in Mandideep, India, has successfully completed a GMP inspection by the United States Food and Drug Administration (U.S. FDA). The inspection was conducted from August 7 to August 11, 2023 and concluded without any observations.

"We are pleased to announce that the U.S. FDA inspection of our Mandideep Unit-2 facility concluded with no observations. This further reaffirms our commitment to superior quality and compliance standards," said Nilesh Gupta, Managing Director, Lupin.

Shares of Lupin Limited was last trading in BSE at Rs. 1085.00 as compared to the previous close of Rs. 1099.15. The total number of shares traded during the day was 21738 in over 1501 trades.

The stock hit an intraday high of Rs. 1105.60 and intraday low of 1081.05. The net turnover during the day was Rs. 23723334.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Unit2 Mandideep USFDA Inspection NoObservations